{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:23:20Z","timestamp":1769858600741,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/jjco\/hys110","type":"journal-article","created":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T15:16:25Z","timestamp":1343402185000},"page":"836-844","source":"Crossref","is-referenced-by-count":29,"title":["Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma\u2020"],"prefix":"10.1093","volume":"42","author":[{"given":"Yan","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cincotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"key\n\t\t\t\t20170502104553_HYS110C1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1442-2042.2007.01739.x","article-title":"Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002","volume":"14","author":"Marumo","year":"2007","journal-title":"Int J Urol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C2","article-title":"Cancer statistics update: number of cancer deaths by age and site (2009)","author":"National Cancer Center (Japan)","year":"2010"},{"key":"key\n\t\t\t\t20170502104553_HYS110C3","article-title":"Renal cell carcinoma in China","author":"Li","year":"2008"},{"key":"key\n\t\t\t\t20170502104553_HYS110C4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3346\/jkms.2010.25.8.1113","article-title":"Cancer statistics in Korea: incidence, mortality and survival in 2006\u20132007","volume":"25","author":"Jung","year":"2010","journal-title":"J Korean Med Sci"},{"key":"key\n\t\t\t\t20170502104553_HYS110C5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170502104553_HYS110C6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/14737140.8.3.481","article-title":"Improving outcomes in patients with advanced renal cell carcinoma","volume":"8","author":"Sosman","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"key\n\t\t\t\t20170502104553_HYS110C7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"issue":"uppl 2","key":"key\n\t\t\t\t20170502104553_HYS110C10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","article-title":"Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence","volume":"16","author":"Hutson","year":"2011","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20170502104553_HYS110C11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","article-title":"Temsirolimus, an inhibitor of mammalian target of rapamycin","volume":"14","author":"Rini","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170502104553_HYS110C12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170502104553_HYS110C14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jjco\/hyq047","article-title":"A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors","volume":"40","author":"Fujisaka","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170502104553_HYS110C16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/annonc\/mdg248","article-title":"Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors","volume":"14","author":"Punt","year":"2003","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/0091270007306957","article-title":"Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications","volume":"47","author":"Boni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170502104553_HYS110C18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"key\n\t\t\t\t20170502104553_HYS110C19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1359-6349(06)70557-2","article-title":"Integrated population pharmacokinetic analysis of temsirolimus in cancer patients following weekly IV treatments [abstract 552]","volume":"4","author":"Boni","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"key\n\t\t\t\t20170502104553_HYS110C20","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/42\/9\/836\/14096793\/hys110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T15:39:51Z","timestamp":1561995591000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hys110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2012,7,26]]},"published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hys110","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}